THE BIOLOGY AND TREATMENT OF HUMAN LEUKEMIA AND LYMPHOMA

人类白血病和淋巴瘤的生物学和治疗

• 批准号: 3093532
• 负责人: STUART F SCHLOSSMAN
• 金额: $ 151.38万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 1983
• 资助国家: 美国
• 起止时间: 1983-08-01 至 1989-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3093532
• 关键词: antileukemic agent; human subject; leukemia; lymphocytic leukemia; lymphoma; neoplasm /cancer chemotherapy; neoplasm /cancer immunotherapy; pediatric neoplasm /cancer

In this proposal we have once again emphasized the biology of human leukemia and lymphoma cells and have detailed the accomplishments which have taken place during the course of the second year of this project. The integration of basic studies involving the characterization of hematopoietic stem cells and hematopoietic cells by immunologic, cytologic, and cell culture techniques has already had an impact on our clinical treatment programs. In the next year, we will pursue the development of cell surface and molecular probes for the characterization of the early T cell malignancies utilizing our understanding of T cell receptor gene rearrangements. In addition, we will pursue studies directed at the identification of normal myeloid stem cells and their leukemic clonogenic counterparts utilizing immunologic, cytogenetic and molecular probes. Monoclonal antibodies have proved to be extraordinarily important for diagnosis and increasing evidence will be obtained to support the notion that prognostically important groups can be defined for both B cell and myeloid leukemias. Autologous bone marrow transplant program with J2 and J5 will be continued since the data to date indicates that this approach compares favorably to that obtained in the allogeneic matched system. Studies with the B1 protocol indicate it to be a major new therapeutic modality in previously unresponsive non-Hodgkins's lymphomas. Anti-B-lym peptide antibodies will be utilized for the isolation and characterization of B-lym antigens and it is hoped that these new classes of reagents will complement existing antibodies for the characterization of leukemias. Drs. Kufe, Faller and Frei have demonstrated new pharmacologic approaches which can optimize the treatment of AML, ALL and other tumors. These investigations will continue to exploit combination chemotherapy for the cytoirradication of residual tumor in autologous transplants, asparaginase treatment for ALL and low dose ara-C. Progress made by Drs. Sallan, Weinstein and Mayer in the treatment of ALL and AML utilizing chemotherapy and immunotherapy lend hope to the view that the majority of these diseases will be ultimately curable. The present program has led to multiple interactions of individuals with interests in immunology, molecular biology, cell surface antigens, pharmacology, hematology and oncology. We believe that this integrated approach to cancer treatment and diagnosis has already resulted in a greater understanding of the malignant cell and its control.

在这个提案中，我们再次强调了人类的生物学 白血病和淋巴瘤细胞，并详细介绍了这些成就 是在该项目的第二年进行的。 这 涉及表征的基础研究的整合 造血干细胞和造血细胞通过免疫学、细胞学、 细胞培养技术已经对我们的临床产生了影响 治疗方案。 明年我们将继续努力发展 用于表征早期 T 的细胞表面和分子探针 利用我们对 T 细胞受体基因的理解来治疗细胞恶性肿瘤 重新安排。 此外，我们将针对 正常骨髓干细胞及其白血病克隆形成的鉴定 利用免疫学、细胞遗传学和分子探针的对应物。 单克隆抗体已被证明对于 将获得诊断和越来越多的证据来支持这一观点 可以为 B 细胞和 骨髓性白血病。 J2和自体骨髓移植计划 J5 将继续下去，因为迄今为止的数据表明这种方法 与同种异体匹配系统中获得的结果相比更为有利。 B1 方案的研究表明它是一种主要的新疗法 先前无反应的非霍奇金淋巴瘤的治疗方式。 抗B淋巴细胞 肽抗体将用于分离和表征 B-lym 抗原，希望这些新型试剂能够 补充现有的用于白血病表征的抗体。 博士。 Kufe、Faller 和 Frei 展示了新的药理学方法， 可以优化 AML、ALL 和其他肿瘤的治疗。 这些 研究将继续探索联合化疗 自体移植物中残留肿瘤的细胞照射，天冬酰胺酶 ALL 和低剂量 ara-C 的治疗。 博士取得的进展。萨兰, Weinstein 和 Mayer 利用化疗治疗 ALL 和 AML 和免疫疗法给大多数这些疾病的观点带来了希望 最终是可以治愈的。 目前的计划已导致多个 对免疫学、分子学感兴趣的个体之间的相互作用 生物学、细胞表面抗原、药理学、血液学和肿瘤学。 我们 相信这种癌症治疗和诊断的综合方法已经 已经导致对恶性细胞及其它的更深入的了解 控制。